Mycobacterial Diseases
ISSN: 2161-1068
OPEN ACCESS Freely available online
Opinion Article

# Use of Multidrug Therapy Regimen for Hansen Disease Patients

**Sahim Nawaz***

*Department of Bacteriology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana*

## DESCRIPTION

Leprosy, also known as Hansen's disease, is a chronic infectious disease caused by the bacterium *Mycobacterium leprae*. This disease primarily affects the skin, the peripheral nerves, and the mucous membranes of the upper respiratory tract. Leprosy is a treatable disease, and with the use of leprostatic agents, patients can recover and prevent the spread of the disease. There are several leprostatic agents available for the treatment of leprosy. These agents are classified into two categories: Multidrug Therapy (MDT) and other drugs.

Multidrug Therapy (MDT) is the standard treatment for leprosy recommended by the World Health Organization (WHO). Dapsone is a bacteriostatic drug that inhibits the growth of *Mycobacterium leprae*. Clofazimine is also a bacteriostatic drug that is effective against *Mycobacterium leprae*, but its exact mechanism of action is not fully understood. The use of MDT has several advantages. It is highly effective in curing leprosy, with a cure rate of more than 95%. It is also relatively safe and well-tolerated by patients. MDT is also cost-effective and can be easily administered in resource-limited settings. Furthermore, MDT has contributed significantly to the reduction in the global burden of leprosy. Other drugs that are used in the treatment of leprosy include minocycline, ofloxacin, and clarithromycin. Minocycline is a tetracycline antibiotic that has been found to be effective against *Mycobacterium leprae*. Ofloxacin is a fluoroquinolone antibiotic that is also effective against *Mycobacterium leprae*. Clarithromycin is a macrolide antibiotic that has shown promising results in the treatment of leprosy. These drugs are typically used in combination with MDT in cases where the patient is intolerant to one of the drugs or in cases where the patient has a relapse.

The choice of leprostatic agents for the treatment of leprosy depends on several factors, including the type of leprosy, the severity of the disease, and the patient's tolerance to the drugs. In general, MDT is the first-line treatment for leprosy, and other drugs are used as adjuncts in cases where MDT is not effective. Leprosy is a curable disease, but early diagnosis and treatment are crucial in preventing disability and deformity. The diagnosis of leprosy is based on clinical examination and the presence of characteristic skin lesions. The diagnosis is confirmed by the detection of acid-fast bacilli in skin smears or biopsy specimens.

The treatment of leprosy requires a multidisciplinary approach. In addition to drug therapy, patients with leprosy may require surgery to correct deformities and prevent disability. Rehabilitation and social support are also important in helping patients reintegrate into their communities. Prevention of leprosy is achieved through early detection and treatment of cases and contact tracing of infected individuals. Vaccines are also being developed for the prevention of leprosy, but these are still in the experimental stage.

## CONCLUSION

Leprosy is a curable disease, and with the use of leprostatic agents, patients can recover and prevent the spread of the disease. Multidrug Therapy (MDT) is the standard treatment for leprosy and has several advantages, including high efficacy, safety, and cost-effectiveness. This therapy involves the use of a combination of drugs that includes rifampicin, dapsone, and clofazimine. Rifampicin is a bactericidal drug that kills the *Mycobacterium leprae* bacterium.

**Correspondence to:** Sahim Nawaz, Department of Bacteriology, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana, E-mail: sahimnawaz170@gmail.com

**Received:** 01-May-2023, Manuscript No. MDTL-23-23970; **Editor assigned:** 03-May-2023, Pre QC No. MDTL-23-23970 (PQ); **Reviewed:** 17-May-2023, QC No. MDTL-23-23970; **Revised:** 24-May-2023, Manuscript No. MDTL-23-23970 (R); **Published:** 31-May-2023, DOI: 10.35248/2161-1068.23.13.348.

**Citation:** Nawaz S (2023) Use of Multidrug Therapy Regimen for Hansen Disease Patients. Mycobact Dis. 13:348.